Maze Therapeutics

what makes us different

about us

At Maze, we envision a world where genetic insights inspire new medicines. We will navigate the breadth of genetic information available to us to understand how genetic modifiers can provide protection against severe diseases.

By bringing together human genetics and functional genomics into a platform driven by scientific pioneers and experienced company builders, we will develop new medicines that change the course of diseases.

our team

Jason Coloma

Ph.D., President, Chief Mazer

Tim Behrens

M.D., Senior Vice President, Human Genetics

Matt Brauer

Ph.D., Vice President, Data Science

Matt Krause

Senior Vice President, Human Resources

Eric Green

M.D., Ph.D., Vice President, R&D

David Morgans

Ph.D., Senior Vice President, Drug Discovery

Tara Nickerson

Ph.D., Chief Business Officer

founders

Mark Daly, Ph.D.

Broad Institute

Dr. Mark Daly is an institute member of the Broad Institute, co-director of the Program in Medical and Population Genetics and the director of the Institute for Molecular Medicine Finland. His research primarily focuses on the development and application of…

View full bio

Stephen Elledge, Ph.D.

Harvard Medical School and Brigham and Women’s Hospital

Dr. Stephen Elledge is a world-renowned leader in the field of the genetics, biochemistry, genomics, and proteomics of cancer cell biology. He is currently the Gregor Mendel Professor of Genetics and Medicine at Harvard Medical School and Brigham and Women’s…

View full bio

Aaron D. Gitler, Ph.D.

Stanford University

Dr. Aaron Gitler is professor of genetics at Stanford University. One of his most pivotal discoveries was the identification of a major genetic contributor to amyotrophic lateral sclerosis (ALS). Aaron’s team recently demonstrated that inhibiting this gene markedly extends lifespan…

View full bio

Sekar Kathiresan, M.D.

Massachusetts General Hospital and Broad Institute

Dr. Sek Kathiresan, a physician scientist and a human geneticist, is the CEO of Verve Therapeutics, director of the Center for Genomic Medicine (CGM) at Massachusetts General Hospital (MGH), Ofer and Shelly Nemirovsky MGH Research Scholar, director of the Cardiovascular…

View full bio

Jonathan S. Weissman, Ph.D.

University of California, San Francisco

Dr. Jonathan Weissman is professor and vice chair of the Department of Cellular & Molecular Pharmacology at the University of California, San Francisco and an investigator of the Howard Hughes Medical Institute. He serves as the co-director of the Innovative…

View full bio

board of directors

Charles Homcy, M.D.

Chairman of the Board; Partner, Third Rock Ventures

Dr. Charles Homcy is a partner at Third Rock Ventures, where he focuses on the formation of companies that discover and develop novel therapeutic approaches. He brings significant experience building and leading successful biotech companies and has played an integral…

View full bio

Vineeta Agarwala, M.D., Ph.D.

Venture Partner, GV

Dr. Vineeta Agarwala is a physician-scientist who is passionate about the intersection of data science and health care. As a director of product management at Flatiron Health, she has led development of national-scale databases that integrate clinical and genomic data…

View full bio

Jason Coloma, Ph.D.

President, Chief Mazer

Dr. Jason Coloma is the CEO of Maze Therapeutics. Prior to his appointment to CEO, he was Maze’s interim chief operating officer and a venture partner at Third Rock Ventures, where he was instrumental in the founding and launch of…

View full bio

Robert Nelsen

Co-Founder & Managing Director, ARCH Venture Partners

Robert Nelsen is a co-founder and a managing director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the early sourcing, financing and development of more than 100 companies, including 19 that have…

View full bio

Richard Scheller, Ph.D.

Former head of therapeutics and chief scientific officer, 23andMe

Dr. Richard Scheller is the former head of therapeutics and chief scientific officer of 23andMe. Prior to his role there, he spent 14 years at Genentech where he was executive vice president of research and early development. He served on…

View full bio

Jeffrey Tong, Ph.D.

Partner, Third Rock Ventures

Dr. Jeffrey Tong is a partner with Third Rock Ventures, where he focuses on drug discovery and development across the firm’s portfolio. He is chairman of Ambys Medicines, and also serves on the board of Nurix Therapeutics. Prior to joining…

View full bio

Eli Casdin (observer)

Chief Investment Officer and Founder, Casdin Capital

Eli Casdin founded Casdin Capital in 2011. For the last 16 years, he has analyzed and invested in disruptive technologies and business models in life sciences and healthcare. Prior to founding Casdin Capital, Eli was a vice president in at…

View full bio

Jeffrey Finer, M.D., Ph.D. (observer)

Venture Partner, Third Rock Ventures

Dr. Jeff Finer is a venture partner at Third Rock Ventures, where he focuses on drug discovery and development opportunities across the firm’s portfolio. Jeff brings to Maze more than 30 years of research and clinical experience, including 20 years…

View full bio

Michael Rome, Ph.D. (observer)

Director, Foresite Capital

Dr. Michael Rome joined Foresite Capital in 2016 and is active in the firm’s public and private market investments. Michael has experience investing across diverse therapeutic areas and has board observer roles (past and present) at Turning Point Therapeutics, Arcus…

View full bio

investors

Third Rock
Arch
Google Ventures
Foresite
Casdin Capital
Alexandria

Charles Homcy

M.D., CEO; Partner, Third Rock Ventures

Dr. Charles Homcy is a partner at Third Rock Ventures, where he focuses on the formation of companies that discover and develop novel therapeutic approaches. He brings significant experience building and leading successful biotech companies and has played an integral role in the launching and building of Third Rock Ventures’ portfolio companies, including Ambys Medicines, Global Blood Therapeutics, Pliant Therapeutics, Relay Therapeutics, Goldfinch Bio, CytomX and MyoKardia.